AzaFol
Phase 2Small molecule
AzaFol is one of 13 small molecule programs targeting Vasculitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Vasculitis
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Plaquenil
Jazz PharmaceuticalsApproved
Imuran
LLegacy Health System
Approved
Campath
GGenzyme, a Sanofi Company
Approved
Tavneos
AmgenPhase 3
Gazyva
RochePhase 2
Fabhalta
NovartisPhase 2
NM8074
NNovelMed Therapeutics
Phase 2
Arava
SanofiPreclinical
CAR-T Therapy
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AzaFol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details